Scorpan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Scorpan

What is Scorpan? (Hyoscine Butylbromide)

Property Description
Active ingredient Hyoscine Butylbromide
Form Tablets, Injectable Solution, Suppositories
Pharmacological class Antispasmodic Agent, Anticholinergic Drug
Common Use Relief from Smooth Muscle Spasm (Cramping)
Origin Semi-synthetic, Quaternary Ammonium Derivative

What Type of Medicine is Scorpan?

Scorpan is a medicinal entity whose active component is Hyoscine Butylbromide (N-Butylscopolammonium bromide), classifying it as an antispasmodic agent and an anticholinergic drug (parasympatholytic). This compound is defined chemically as a quaternary ammonium derivative, which is a distinguishing structural feature that influences its activity. This specific structure is essential for targeting peripheral smooth muscle. This classification confirms that the medicine’s primary role is to treat involuntary muscle issues.

Forms and Composition of Hyoscine Butylbromide

Hyoscine Butylbromide is prepared in several pharmaceutical preparations, most commonly as film-coated tablets for oral ingestion, injectable solutions for parenteral use (intravenous or intramuscular administration), and sometimes suppositories. This flexibility in dosage form allows options for managing painful, acute episodes, such as when oral dosing is unsuitable. Each preparation contains the key substance and is formulated with appropriate excipients to ensure stability and effective delivery.

What is the General Purpose of Antispasmodic Agents?

As a spasmolytic, the general purpose of Scorpan is to achieve the reduction of smooth muscle tone, offering relief from the discomfort associated with acute visceral spasm. It is used for addressing painful abdominal cramping. Its peripheral selective action means that the therapeutic effect is concentrated on the muscles lining the gastrointestinal, biliary, and genitourinary tracts, helping to normalize function without significantly affecting the central nervous system. This feature ensures the medicine’s action is concentrated on the muscles of the abdomen and pelvis.

Regulatory References

  1. Hyoscine Butylbromide Monograph

What side effects are possible with Scorpan?

Possible Side Effects and Safety Information: Scorpan (Hyoscine Butylbromide)

The officially documented adverse effects of Scorpan are primarily associated with its anticholinergic properties, affecting several System Organ Classes (SOC) including gastrointestinal, ocular, and cardiac systems. Side effects are classified by their documented frequency in regulatory documents.


Frequency-Classified Adverse Reactions

The following are examples of adverse reactions reported in official labeling:

Classification System Organ Class Example Reactions
Common (Reported ge 1/100) Cardiac, Gastrointestinal, Eye Tachycardia (increased heart rate), Dry mouth, Accommodation disorders (transient visual disturbances)
Rare (Reported < 1/1,000) Renal and Urinary Urinary retention (difficulty passing urine)
Not Known (Frequency cannot be estimated) Immune, Vascular, Nervous Anaphylactic shock, Hypotension, Mydriasis, Confusion, Coma

Documented Serious Reactions and Safety Constraints

Official regulatory sources highlight specific serious adverse reactions that have been documented. These include severe anaphylactic shock and acute hypotension and severe tachycardia, particularly when the medicine is administered via injection (parenteral route).

Population-specific safety considerations are noted for individuals with certain pre-existing conditions. The medicine is contraindicated in untreated narrow-angle glaucoma due to the risk of precipitating elevated intraocular pressure. Caution is also advised in patients with existing cardiac conditions susceptible to tachycardia and those with conditions predisposing them to urinary or intestinal obstruction.

As a safety-related restriction, patients who experience accommodation disorders or dizziness are advised in labeling to avoid hazardous tasks such as driving or operating machinery until the visual disturbances completely resolve. Most documented adverse effects are generally described as mild and short-lived.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Scorpan

Overdose Scope

Domain Official Regulatory Statements
Documented overdose presentations Overdosage may present with anticholinergic symptoms including dry mouth (xerostomia), tachycardia, reddening of the skin, urinary retention, and transient visual disturbances.
Severe outcomes The regulatory profile includes severe, life-threatening outcomes such as respiratory paralysis and Cheynes-Stokes respiration (a specific breathing pattern documented in overdose cases).
Population-specific overdose notes Infants and children with spastic paralysis or brain damage may exhibit an increased response. Geriatric patients may experience manifestations such as excitement, agitation, or confusion.
When immediate medical help is required (label-derived phrasing only) Medical advice should immediately be sought if severe, unexplained abdominal pain persists or worsens, or if it occurs with symptoms like fever, vomiting, decreased blood pressure, fainting, or blood in stool. Urgent ophthalmological advice is required for painful, red eye with loss of vision.

Resulting Overdose Structure

Official overdose statements:

  • The required treatment involves the use of parasympathomimetics to counteract effects, and specific procedures such as gastric lavage and administration of activated charcoal for oral poisoning.
  • Catheterisation may be necessary to manage urinary retention, and sympathomimetics may be used to boost circulation as part of supportive management.

Connection to the overall overdose profile

Regulatory documents define the overdose profile of Scorpan by explicitly listing the resulting anticholinergic manifestations and the potential for severe respiratory or cardiovascular complications. Official labeling mandates that immediate medical advice must be sought based on the presence of specific, serious systemic signs accompanying abdominal pain. Furthermore, the documents detail specific procedural interventions required for managing the overdose state.

Therapeutic Uses of Scorpan

What Scorpan Treats: Main Uses and Benefits

Scorpan may be used to help address symptoms related to physical discomfort and systemic imbalance, applying across therapeutic domains where additional symptomatic support is needed. It is commonly used to help with symptomatic relief associated with minor aches and pains due to headache, muscle aches, dental discomfort, backache, and painful menstrual cramps, and to help reduce fever associated with the common cold. This medication may be relevant when short-term symptomatic assistance is needed.

It helps address symptom clusters that may become intense or disruptive, such as swelling and stiffness associated with inflammatory or irritative states. When symptoms intensify, it contributes to improved comfort during these periods, and may assist with maintaining functional stability during temporary symptomatic periods.

“The medication is relevant in clinical settings that involve acute or unstable symptom patterns, offering supportive relief when symptoms interfere with routine activities.”


Quick Fact: Management of Fever


Eligibility and Restrictions for Use

Eligibility Scope

Scorpan (Hyoscine Butylbromide) is approved for use in adults and children aged 6 years and older (for oral tablets). Use in children younger than 6 years is generally not recommended by regulatory bodies. The eligibility profile is primarily defined by a series of absolute contraindications, which exclude certain patient populations.

Classification Population or Condition
Contraindicated Myasthenia Gravis
Contraindicated Megacolon or Paralytic/Obstructive Ileus
Contraindicated Narrow-Angle Glaucoma (untreated)
Contraindicated Prostatic Hypertrophy with urinary retention
Contraindicated Hypersensitivity to the active substance or excipients
Contraindicated Tachycardia, Angina, or Cardiac Failure (for injectable form)

Pregnancy and Lactation Status: Use is not recommended during pregnancy or while breastfeeding. Regulatory documentation indicates that use should be avoided as a precautionary measure due to insufficient data to establish safety in these populations. The medicine requires caution in patients with other pre-existing cardiac conditions or those susceptible to developing urinary or intestinal obstructions.

Connection to the overall eligibility profile: Regulatory documents define eligibility by strictly prohibiting the medicine's use in patients with conditions aggravated by its anticholinergic effect, such as obstructions and glaucoma. This structure establishes clear boundaries for use in high-risk groups, alongside restrictions for pediatric and reproductive populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Scorpan is primarily defined by the pharmacodynamic effects of its active ingredient, Hyoscine Butylbromide, as documented in official regulatory labeling. These interactions result in either an intensified effect, a counteracted effect, or a restriction on the route of administration with certain co-administered substances.

Pharmacodynamic Reinforcement

Co-administration with other medicines that possess antimuscarinic properties is officially documented to intensify the anticholinergic effect. These interacting agents include tricyclic and tetracyclic antidepressants, specific antihistamines, some antipsychotics (e.g., phenothiazines), quinidine, amantadine, and disopyramide. This reinforcement also extends to the cardiac system, where the tachycardic effects of beta-adrenergic agents may be enhanced, a consideration noted as potentially more serious for patients with pre-existing cardiac conditions.

Physiological Counteraction

Substances that oppose gastrointestinal motility, such as dopamine antagonists (e.g., metoclopramide or domperidone), may diminish the therapeutic gastrointestinal effect of both medicines.

Formal Restrictions and Warnings

Regulatory documents classify the combination of the intramuscular injection formulation with anticoagulant drugs as a restriction, due to the documented risk of intramuscular haematoma. The oral formulation carries an excipient-based restriction; because the tablets contain lactose, they are restricted for use in patients with documented hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

Mechanism of Action

Scorpan is an agent that engages specific receptor- or enzyme-mediated signaling pathways. Its activity is concentrated in key mechanistic domains that modify the status of elevated physiological activity.

Modulation of Ion Channel Activity

This domain involves Scorpan's action on various voltage-gated ion channels (e.g., sodium, potassium, and calcium channels) on excitable cells. By interacting with and modulating the opening and closing kinetics of these channels, the drug modifies the sequence of action potential propagation. This modification in early molecular steps results in an altered threshold for neuronal and muscular action potential firing.

Regulation of Key Pathway Mediators

Scorpan acts in systems where specific neurotransmitters or enzymatic mediators are present. The drug binds to or influences receptors and enzymes associated with these mediators (such as muscarinic acetylcholine receptors or key proteolytic enzymes), thereby initiating or suppressing subsequent signaling sequences. This influence modulates the concentration or duration of effect of mediator activity, resulting in an adjustment within targeted signaling cascades.

Influence on Systemic Excitability Cascades

The drug's mechanism engages systems that control rapid physiological responses, such as those related to the autonomic nervous system. By modifying molecular steps in these cascades, Scorpan alters the trajectory of downstream pathway activation, which results in a change in the propagation rate of systemic processes driven by distinct signaling patterns.

Dosage and Administration Information

How to Use Scorpan (Hyoscine Butylbromide)

The administration of Scorpan is structured around its role in managing acute smooth muscle spasm, utilizing both oral and parenteral routes as described for its use.


Administration Routes and Forms

Route Typical Dosing Form Use Pattern
Oral 10 mg or 20 mg Tablets General, non-acute symptomatic management
Parenteral 20 mg/mL Solution (IV, IM, SC) Acute episodes requiring rapid onset in a clinical setting

Standard Dosing and Frequency

For oral use in adults and children over 12 years, the typical dose is 10 mg to 20 mg per dose, taken up to three to five times daily as required. The total oral daily intake should not exceed 80 mg. The oral tablet may be taken with or without food and should be swallowed whole with water.

For parenteral use in acute settings, adults and adolescents over 12 years are typically administered 20 mg to 40 mg by slow injection (IV, IM, or SC). This dose may be repeated after 30 minutes for continuing symptoms, up to a maximum daily dose of 100 mg.


Duration and Procedural Conditions

Scorpan is intended for short-term symptomatic management and should not be used on a continuous daily basis without investigation of the underlying cause. When administered intravenously, the injection must be given slowly over several minutes. For pediatric patients, the oral tablet is generally not recommended for use in children under 6 years.

Recent Clinical Evidence

Research evidence / Overview of studies for Scorpan

Evidence for use in Psoriatic Arthritis

Research has studied Scorpan for individuals with psoriatic arthritis, a condition characterized by fluctuating or episodic manifestations that can cause outcomes related to physical discomfort and impact daily functioning or activity level. The evidence available is largely based on randomized controlled trials and follow-up studies that monitored patient-reported changes over defined time intervals, used in research exploring how symptoms change over time.

These studies explored how the treatment was associated with patterns of change in outcomes linked to inflammatory or irritative states and joint swelling. The findings describe patterns observed in the studies over short-term periods, typically a few months, and help contextualize how patients reported their experience of pain and function while the drug was observed in the study setting.

Evidence for use in Crohn's Disease

Scorpan was evaluated in studies focusing on Crohn's disease, which is one of the conditions involving periods of heightened symptoms and outcomes capturing phases of heightened symptom activity in the digestive system. Research examined the use of Scorpan in research scenarios linked to outcomes linked to inflammatory or irritative states and systemic or functional imbalance.

Evidence for use in Ulcerative Colitis

Scorpan was studied for use in patients with ulcerative colitis, another condition presenting with cycles of stability and flare-ups. The research involved clinical trials conducted during periods of increased symptom activity and studies observing responses over defined time intervals. The goal of this research was observed in trials aimed at addressing outcomes related to systemic or functional imbalance and studies exploring outcomes related to the monitoring of clinical remission.

Long-term studies and follow-up

This section summarizes what is still uncertain about the long-term patterns of using Scorpan. While initial trials provided insight into short-term changes, the long-term effects are not fully established. Follow-up durations were limited in the primary studies. Research is ongoing to understand the durability of response and what is known from observation of subjects in extended duration studies, providing context but not individual predictions.

Evidence in special populations

Studies explored the use of Scorpan in various patient groups beyond the general population, including older adults and those with certain comorbid conditions. For some groups, such as pregnant populations or children, the evidence is limited, and data for certain groups remain insufficient. This means that certainty remains low when applying findings from the general studies to these special groups. Comparative evidence is lacking for patients with complex conditions.

What is still uncertain about Scorpan

This section synthesizes the areas where research has not yet provided definitive information. Evidence quality varies across studies, and some initial findings were mixed regarding certain measures. Research does not determine whether an individual will respond similarly to the group average. The evidence highlights what is known — and what is still uncertain, meaning more study is needed to understand how research findings apply to varying symptom burdens.

Key Studies & References

  1. Sustained Clinical Response with Scorpan in Ulcerative Colitis: The SCOUT-UC Study
  2. Clinical Guideline for the Treatment of Psoriatic Arthritis (ACR/NPF)

Frequently Asked Questions (FAQ)

Common questions about Scorpan (FAQ)


Q: What is the main reason Scorpan is prescribed?

Regulatory documents indicate that Scorpan is prescribed for the relief of smooth muscle spasm. This includes spasms associated with conditions affecting the gastrointestinal tract and the genitourinary system.


Q: Is Scorpan used to treat more than one condition?

Yes, official documents describe the use of Scorpan for symptomatic relief in both the gastrointestinal system and the genitourinary system. This means it addresses spasms related to multiple conditions in these two areas.


Q: What are the most commonly reported side effects of Scorpan?

Official product information describes common side effects such as dry mouth and a fast heart rate (tachycardia). Uncommon events reported in regulatory data include certain skin reactions and difficulty passing urine (urinary retention).


Q: How long do common side effects from Scorpan usually last?

Regulatory documents generally do not provide a specific duration for common side effects. However, official information notes that transient visual disturbances sometimes reported after the injection form of the medication are noted to usually resolve spontaneously.


Q: Are there any serious or less common side effects associated with Scorpan?

Yes, serious events such as anaphylaxis, which includes severe shock, have been observed, particularly when the drug is given by injection. Less common effects listed in regulatory reports include difficulty passing urine and various skin reactions.


Q: Is it normal to feel a little dizzy when first starting Scorpan?

Official documents list dizziness as a possible adverse effect of Scorpan. If dizziness or any other new symptoms are experienced, it is important that these symptoms are reviewed by a healthcare provider.


Q: What is the risk of having an allergic reaction to Scorpan?

The medication is contraindicated (should not be used) in patients with known hypersensitivity to the drug's components. Serious allergic reactions, including anaphylaxis and shock, have been reported in regulatory sources, especially following the injection form.


Q: Does Scorpan interact with common over-the-counter pain relievers?

Official product information indicates that the effects of Scorpan may be intensified when taken with other medicines that have anticholinergic properties. This includes certain classes of drugs, such as some antidepressants, antihistamines, and antipsychotics.


Q: Can Scorpan be taken with supplements or vitamins?

Official documents describe interactions with certain drug classes (e.g., anticholinergics, dopamine antagonists). For safety, all supplements and vitamins should be disclosed to a healthcare professional.


Q: Is it safe to consume alcohol while taking Scorpan?

Official documents and patient counseling information consistently advise patients to abstain from alcohol while taking this medication. This guidance is in place to reduce the potential for adverse effects or interactions.


Q: Does Scorpan interact with other prescription medications?

Yes, official information describes potential drug-drug interactions. For example, the medication may intensify the effects of other drugs with anticholinergic properties and may diminish the effects of dopamine antagonists like metoclopramide.


Q: When should I expect to notice the effects of Scorpan?

Official documents do not typically specify an exact timeframe for the effects of the oral tablet. However, the injection form is described as having a rapid onset of action for acute situations.


Q: Does Scorpan cause tiredness or affect my ability to concentrate?

The drug may cause temporary disturbances in vision, known as accommodation disturbances, and dizziness. Official documents advise caution when performing tasks like driving or operating machinery if these effects are experienced.


Q: Is Scorpan a type of antibiotic, anti-inflammatory, or something else?

Official therapeutic classifications describe the medication as an anticholinergic or antispasmodic drug. It is neither an antibiotic nor a primary anti-inflammatory agent.


Q: What kind of studies were done to determine the uses of Scorpan?

Regulatory approval documents cite a body of clinical data and research, including controlled trials and pharmacological studies. This evidence is used to support the approved indications and safety profile of the medication.


Q: What are the restrictions on who can take Scorpan?

Official labeling lists multiple conditions that contraindicate the use of Scorpan. These include untreated narrow-angle glaucoma, prostatic hypertrophy with urinary retention, myasthenia gravis, and certain gastrointestinal tract obstructions.


Q: Can people with kidney problems use Scorpan?

Official warnings indicate that caution has been advised for patients who have impaired liver or kidney functions. Any use in these patient groups requires specific medical review and oversight.


Q: Is Scorpan appropriate for use in older adults?

Official documents recommend using caution in older patients. This is due to the potential for anticholinergic complications or an increased risk of adverse effects on the central nervous system.


Q: Are there special considerations for children using Scorpan?

The oral tablet is generally not recommended for children under 6 years of age. Specific age cutoffs and dosing recommendations for children vary by jurisdiction and must be determined by a healthcare provider.


Q: What is known about taking Scorpan during pregnancy or while breastfeeding?

Official information indicates that there are limited data available on the use of this drug during pregnancy and breastfeeding. Therefore, use during these periods is generally not recommended as a precautionary measure.


Q: What happens if I forget to take a dose of Scorpan?

Since the medication is typically prescribed for short-term, 'as needed' symptomatic relief, official instructions focus primarily on the maximum dose allowed within a 24-hour period. Guidance on missed doses should be sought directly from a healthcare provider.


Q: What should I do if I experience a side effect not listed in the patient information?

Official warnings stress the importance of seeking review if severe, unexplained abdominal pain persists or worsens. This is especially true if the pain occurs alongside symptoms like fever, vomiting, or blood in the stool; immediate medical review is necessary.


Q: Does Scorpan have any potential drug-disease interactions mentioned in official documents?

Yes, regulatory documents list specific diseases and conditions that are considered contraindications. These include myasthenia gravis, untreated narrow-angle glaucoma, and certain cardiac conditions like tachycardia or cardiac failure.


Q: Can Scorpan affect my mood or sleep patterns?

While the drug does not easily pass into the brain, official documents note that psychiatric disorders such as confusion or agitation may rarely occur, particularly following injection. These effects may indirectly influence mood or sleep.


Q: Is Scorpan safe to use if I have a history of heart problems?

Patients with certain heart conditions, such as cardiac failure, coronary heart disease, or arrhythmia, should use the medicine with caution. Official warnings indicate the drug may potentially cause a fast heart rate (tachycardia) or low blood pressure (hypotension).


Q: Are there specific official warnings or precautions for Scorpan?

Official precautions include the risk of serious allergic reactions like anaphylaxis, and specific caution for patients with conditions like narrow-angle glaucoma. The patient information emphasizes the need for medical investigation if severe, unexplained abdominal pain persists.


Q: What is the risk of having a serious interaction with Scorpan?

Official documents warn that for patients using anticoagulants (blood thinners), the intramuscular injection form of the drug should be avoided due to the risk of hematoma. There is also a risk of intensified effects when combining it with other anticholinergic drugs.


Q: What are the official guidelines regarding the storage of Scorpan?

Official instructions note that the product generally does not require special storage conditions, often specified as storage below 25 C or room temperature. Precise guidance is available in the official patient leaflet.


Q: Can Scorpan be taken by people with liver issues?

Caution has been advised in regulatory documents for patients who are known to have impaired liver or kidney functions. Your doctor will need to review this factor when determining appropriateness.


Q: What is the scientific basis for how Scorpan treats the condition?

The scientific basis is its classification as an anticholinergic drug. It works by blocking the effects of a specific neurotransmitter on the smooth muscle lining the walls of the gastrointestinal and genitourinary tracts, helping to relieve spasms.


Q: Is Scorpan subject to any special prescription monitoring or controls?

Official labeling specifies the product's legal status, such as whether it is prescription-only or available over-the-counter in certain regions. Standard patient information does not typically mention special monitoring programs.


Q: Is it possible to take Scorpan with antacids?

Official information indicates that antacids and certain anti-diarrhea drugs may lower the drug's absorption into the body. To minimize this, the product label advises taking this medication at least 1 hour before taking those other products.


Q: Does the drug label mention any known genetic factors that affect Scorpan's effectiveness?

Official warnings relate to hereditary conditions like galactose intolerance or total lactase deficiency. These warnings are due to the presence of excipients (inactive ingredients) like lactose in some tablet formulations.


Q: What activities or tasks should be avoided while adjusting to Scorpan?

Official documents advise caution when performing tasks that require concentration, such as driving a car or operating machinery. This is especially relevant if you experience dizziness or temporary visual disturbances.


Q: What does the term 'contraindication' mean for Scorpan?

The term contraindication refers to specific conditions or circumstances where the medication should not be used. For Scorpan, these include conditions like untreated narrow-angle glaucoma or myasthenia gravis, where the risks are considered to outweigh the benefits.


Q: Are there common drug-drug interactions that are easy to overlook with Scorpan?

Interactions may be overlooked because they involve medicines that also possess anticholinergic effects. These are found in various over-the-counter and prescription drugs, and their combined effect with Scorpan may be intensified.


Q: What are the official patient resources available for Scorpan?

Official drug documents often include a Patient Medication Information section or a detailed patient leaflet. These resources are usually made available by a healthcare professional or pharmacist.


Q: What is the difference between the brand name Scorpan and its generic equivalent?

Official documents confirm that while the active ingredient (Hyoscine Butylbromide) is identical, the brand-name tablet and generic equivalent may contain different inactive ingredients (excipients). Common excipients include lactose or sucrose, which vary by manufacturer.


Q: What happens if I accidentally take more than the recommended dose of Scorpan?

Regulatory information describes potential signs of overdose, which can include a very fast heart rate (tachycardia), severe dry mouth, difficulty passing urine (urinary retention), and transient visual disturbances. If these signs are observed, it indicates that urgent medical review is required.


Q: Does the efficacy of Scorpan decrease over time?

Official warnings advise against taking the medication on a continuous daily basis or for extended periods. This is because prolonged use without investigation of the underlying cause is not recommended in the official guidelines.

How should Scorpan be stored and disposed of?

The storage and disposal of Scorpan (Hyoscine Butylbromide) must strictly follow official regulatory instructions to ensure stability.

Storage and Protection

Dosage Form Required Storage Condition
Tablets Store below 30°C and in the original package to protect from light.
Injection Ampoules Store below 30°C or as otherwise specified, in the outer carton to protect from light.

The injection is for single-use; once opened, it must be used immediately and any unused contents discarded. Diluted solutions have an in-use stability of up to 24 hours at 2°C to 8°C if prepared under aseptic conditions. All forms must be kept out of the sight and reach of children.

️ Disposal Requirements

Expired or unused medicine must not be disposed of via wastewater or household waste. Disposal must be in accordance with local requirements, typically by returning the product to a pharmacist or using a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Scorpan found in:

A-Z Index: